FDA Approves First-Line Drug for Bladder Cancer

Roche announced this week that its bladder cancer treatment, Tecentriq, has won FDA approval to treat advanced bladder cancer. The advanced approval decision makes Tecentriq the first pharmaceutical to be used as a first-line treatment of advanced bladder cancer....

Google to Host Long-Term Clinical Study into Human Biology

Google has announced an upcoming, long-term study into the lives of “healthy” adults. The 10,000 person study into human biology will be conducted by Verily, which was formerly known as Google Life Sciences. Points of interest in the study may be the correlation...

First Small Molecule Hearing Loss Therapy Begins Financing

Aiming to rectify noise-induced hearing loss, Frequency Therapeutics has begun financing for a small-molecule therapy which will help re-grow small hairs within the inner ear. This therapy is designed to mimic CRISPR and gene therapies to stimulate remaining cells...

Neurocrine Receives Approval for First Tardive Dyskinesia Treatment

Neurocrine received approval from the FDA this week to begin commercialization of Ingrezza, currently the only FDA-approved treatment of tardive dyskinesia. The drug will help combat involuntary motions caused by the disease. As of the approval, Ingrezza is the first...

Hydrogen-Heavy Austedo Receives FDA Approval

After releasing drug circulation details last week, the FDA has approved Teva’s Austedo for commercialization. Austedo is meant to reduce the chorea associated with Huntington’s disease. Last week we reported that Teva had replaced molecules in Austedo for “heavy...

Respiratory Assistance Device to Begin US Clinical Testing

ALung Technologies has announced its plans to begin US clinical trial testing after the FDA awarded the medical device firm Expedited Pathway Access for its artificial lung technology. The device, HemoLung Respiratory Assist System, was launched in 2013 outside of the...